Kathy Rowlen, Ph.D.
Chief Executive Officer and Co-founder
Dr. Kathy Rowlen`s career has spanned both academia and business over the past three decades. Rowlen was an award winning Professor of Chemistry at the University of Colorado in Boulder from 1991 to 2008; recognition included National Science Foundation Career Award, Beckman Foundation Young Investigator, Research and Creative Work Faculty Fellowship, and Inventor of the Year in 2006. In 2003 Grand Valley State University honored her as a Distinguished Alumna. Dr. Rowlen is inventor/co-inventor on numerous patents, has published over 85 scientific papers, and has given hundreds of scientific talks. After co-founding InDevR in 2003, Dr. Rowlen transitioned to a full time position as its Chief Executive Officer in 2008. Under her leadership the company has experienced balanced growth and has successfully translated fundamental research into high-impact commercial products. InDevR has received a number of awards including Colorado Companies to Watch (2010), Innovative Company of the Year (BizWest IQ Awards, 2015), and Innovative Product of the Year (BizWest IQ Awards, 2015).
Dr. Rowlen received her B.S. (with honors) in Chemistry at Grand Valley State University and her Ph.D. in Chemistry at the University of Colorado, Boulder. She serves on the Board of Directors for InDevR, 2B Technologies, and ViroCyt Inc.
Laura Kuck, Ph.D.
Executive Vice President and Co-founder
Dr. Laura Kuck has held a number of senior management positions during her 20+ year career including Scientific Advisor for the USFDA, Laboratory Director for Onsite Laboratories, Quality Assurance Manager for Dames and Moore, and Laboratory Director for Resna Laboratories, and was an award-winning Chemistry instructor at the University of Colorado in Boulder. At InDevR, Dr. Kuck specializes in basic research as the first step toward translating ideas into products. Her efforts ultimately led to the creation of several InDevR products including ampliPHOX, Virus Counter, and VaxArray potency assays. Currently Dr. Kuck serves as the scientific liaison with collaborators in the vaccine industry.
Dr. Kuck received her B.S. and M.S. degrees from the University of California, Davis and her Ph.D. in Chemistry from the University of Colorado, Boulder.
John Birks, Ph.D.
Executive Vice President and Co-founder
In addition to his leadership role at InDevR Inc., Dr. John W. Birks is co-founder and President of 2B Technologies, Inc. in Boulder, Colorado. Under Birks’ leadership, 2B Technologies has sold more than 5,000 instruments for air pollution monitoring worldwide. He is also Professor Emeritus of Chemistry and Biochemistry and Fellow Emeritus of the Cooperative Institute for Research in Environmental Sciences (CIRES) of the University of Colorado at Boulder where he served on the faculty for 25 years. Dr. Birks has received numerous awards for outstanding science including Alfred P. Sloan and John Simon Guggenheim Fellowships, the Thomas Jefferson Award of the University of Colorado, the Witherspoon Peace and Justice Award, the Colorado Section Award of the American Chemical Society, the Leo Szilard Award for Physics in the Public Interest of the American Physical Society, the American Chemical Society Award for Creative Advances in Environmental Science and Technology, and the 2000 Hazel Barnes Prize, which is the highest faculty award of the University of Colorado
Dr. Birks received his B.S. (high honors) from the University of Arkansas and his M.S. and Ph.D. from the University of California, Berkeley. He serves on the Board of Directors for InDevR, 2B Technologies, and the GO3 Foundation.
Chief Commercial Officer
Dawn Bitz has been a successful corporate executive, entrepreneur and consultant during her 20+ year career. Ms. Bitz has held prominent positions with multi-billion dollar medical device and pharmaceutical companies, consulted for small and mid-cap companies, led mergers and integrations of $250M acquisitions, and has held $500M+ P&L responsibilities globally. Early in Ms. Bitz’ career she worked clinically on the ambulance and in the hospital and managing both pharmaceutical and medical device research studies. She translated that foundation into a successful business management and commercial career. Ms. Bitz has led global marketing, sales, product development, business development and commercial operations for companies like Covidien, Boston Scientific and UCB Pharma. She also founded and sold a consumer product goods and technology company. Ms. Bitz will lead InDevR’s commercial efforts, including product sales, marketing, business development and licensing, communications, public relations and investor relations.
Ms. Bitz holds undergraduate degrees in biology and chemistry from Texas Christian University and is a registered nurse and paramedic.
Chief Operations Officer
Ms. Rodriguez has led InDevR`s Finance and Operations departments since the company was founded. She has managed more than $30 M in non-dilutive funding and under her leadership the company has consistently and diligently complied with all Federal Acquisition Regulations requirements. Ms. Rodriguez oversees all procurement and subcontracting procedures, financial and account aspects of cost control systems, and compliance with public laws and regulations. Within Operations, she manages facilities and human resources as well as InDevR`s quality system, ensuring company-wide adherence to the quality policy.
Ms. Rodriguez received her B.S. in Business Administration, Operations Management from the University of Colorado, Boulder. She proudly serves as a Board Member for the GO3 Foundation, a novel education program in science, technology and the environment.
Erica Dawson, Ph.D.
Chief Technical Officer
Dr. Erica Dawson has been integral in leading the research and development as well as the product transfer of multiple commercial products at InDevR since 2006. Dr. Dawson manages InDevR’s cross-functional research and development department, guiding and overseeing the development of the company’s extensive technology portfolio. Additionally, she collaborates with production, customer service, sales and marketing to promote the commercial success of these technologies. Dr. Dawson acts as the program manager or principal investigator on numerous government-funded contracts and grants including the $14.7M contract with the Biomedical Advanced Research and Development Authority (BARDA) for FluChip-8G. Dr. Dawson has over 10 years of Project/Program Management, experiential instrumentation and medical device development experience.
Dr. Dawson earned her Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill, holds a B.S. (summa cum laude) from Hartwick College in Oneonta, NY, and completed her postdoctoral training at the University of Colorado at Boulder. Erica has published a wide number of high impact scientific publications, and is a named inventor on numerous issued or pending US and worldwide patents.